COVID-19 pandemic: more than 200 oncology clinical trials suspended

  • Upadhaya S & al.
  • Nat Rev Drug Discov
  • 18 mai 2020

  • Par Pavankumar Kamat
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • According to an analysis of data from ClinicalTrials.gov, more than 200 interventional oncology clinical trials were suspended in March and April 2020 because of the COVID-19 pandemic.
  • Another survey indicates that most institutions in the United States and Europe are enrolling new patients at lower rates.

Why this matters

  • The COVID-19 pandemic has caused significant disruption in clinical research globally. 

Key highlights

  • A survey of 36 investigators showed that only 20% and 14% of institutions in the United States and Europe, respectively, continued to enroll patients at the usual rate.
  • In contrast, 60% of institutions in Asia reported no change in enrollment rates.
  • 60% of investigators stated that COVID-19 had "moderate" or "high" impact on causing delayed or canceled patient visits.
  • Data from ClinicalTrials.gov showed that 62 interventional oncology trials were suspended in March and 139 in April. 
  • Of these, 29 were phase 1, 72 were phase 2, 11 were phase 3, and the rest were classified as "other."
  • A separate analysis of a subset of clinical trials run by IQVIA showed that milestone delays (16%) were the most reported risk as a result of the COVID-19 pandemic.